The test

What is INNOVATIO-ND2?

A predictive test based on protein biomarkers in blood, linked to the onset and progression of kidney disease in people with type 2 diabetes.

How it works

INNOVATIO-ND2 is an ELISA assay developed and validated by Omics Global Solutions under a technology license from Proteomics International and its PromarkerD™ algorithm.

It measures three blood proteins directly linked to progressive kidney damage (ApoA4, CD5L and IGFBP3) and combines them with the patient's clinical variables (age, HDL cholesterol and eGFR). The algorithm returns one report with two results:

  • Diagnosis: whether the patient already has diabetic kidney disease.
  • Prognosis: the risk of developing it over the next 4 years or, if already present, how fast kidney function is declining.

Because the test reflects changes in risk factors, it shows whether the prevention plan is working from one test to the next.

What is it for?
To act before damage occurs: clinical measures and lifestyle changes that keep the risk from advancing to kidney failure, dialysis or transplant.
Key facts

CPT 0385U · Covered by Traditional Medicare, MCS (Advantage and commercial) and MMM (Advantage and Vital).

Processed by Immuno Reference Lab. Test registered with the Department of Health as an LDT.

See the scientific evidence →

Three risk levels, clear next steps

Low risk
Does not mean "no risk".Standard diabetes care.Repeat in 12 months
Medium risk
Kidney-protective medications; avoid nephrotoxic drugs (NSAIDs).Tight control of blood pressure, lipids and HbA1c; smoking, alcohol and weight.Repeat in 6 months
High risk
The medium-risk plan, with greater intensity and urgency.Candidate for kidney-protective therapy (ACEi/ARB, SGLT2i, GLP-1 RA, finerenone).Repeat in 3–4 months